galantamine clinical trials

From Aaushi
Jump to navigation Jump to search

Introduction

Galantamine in AD: Galantamine USA-1 Study Group[1]

Treatment:

Results:

galantamine improves global & cognitive symptoms at doses > 16 mg/day, in patients with mild to moderate Alzheimer's disease for at least 6 months.[2]

Two unnamed investigational trials[3]

2000 subjects

Results:

* April 1, 2005: Ortho-McNeil Neurologics modified the PRECAUTIONS section of the Prescribing Information for Reminyl (galantamine).

More general terms

Additional terms

References

  1. 1.0 1.1 Raskind MA, Peskind ER, Wessel T, Yuan W, Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54:2261, 2000 PMID: https://www.ncbi.nlm.nih.gov/pubmed/10881250
  2. 2.0 2.1 Cochrane Reviews http://www.cochrane.org/reviews/en/ab001747.html
  3. 3.0 3.1 Internal Medicine News, March 1, 2005 FDA Medwatch http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Reminyl